US FDA Approves Subcutaneous Opdivo, Extending Key BMS Franchise Into 2030s
Injection Cleared 10 Years After I.V. Product
With loss of exclusivity for Opdivo looming in 2028, Opdivo Qvantig will help BMS retain at least some of the revenue for its brand-name blockbuster after biosimilars for the I.V. version hit in 2029.
